Effectiveness and Safety of New Dose of Copaxone® Compared to the Currently Approved Dose
- Study Title
- A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxoneֲ® Compared to Copaxoneֲ® 20mg, the Currently Approved Dose
- Teva Identifier
- 9006
- ClinicalTrials.gov Identifier
- NCT00202982
- Study Status
- Completed
- Trial Condition(s)
- Relapse-Remitting Multiple Sclerosis
- Interventions
- Drug: glatiramer acetate 20 mg | Drug: glatiramer acetate 40 mg
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 Years to 50 Years
- Trial Duration
- 08/01/2003 - 09/01/2005
- Phase
- Phase 2
